Long Ideas - Editor’s note: This trade was sent to PropThink Premium members on Friday, August 30. Purchased Sept 28 calls were good for more than 70% by the close … Continue Reading
Read NowLong Ideas - ChemoCentryx (CCXI), which we originally recommended on August 5 as a play on upcoming Phase III data for the company’s lead drug candidate vercirnon, has … Continue Reading
Read NowLong Ideas - On Tuesday September 3rd, we hosted an interview and Q&A with Sunshine Heart (SSH) CEO David Rosa; a transcript of the call is available at … Continue Reading
Read NowLong Ideas - Orexigen (OREX) is getting interesting again. The obesity drug developer – perhaps Goldilocks’ perfect bowl after two previous attempts (ARNA, VVUS) – iterated this week that … Continue Reading
Read NowLong Ideas - Last December, we called Orexigen (OREX) the obesity stock to own in 2013. Thus far, we’ve been spot on. Arena (ARNA) and Vivus (VVUS) have … Continue Reading
Read NowLong Ideas - BioLife Solutions, the Bothell, WA based supplier of biopreservation media products and contract manufacturer, has climbed over 100% since our April report on the company. … Continue Reading
Read NowLong Ideas - Curis (CRIS) early in August added two new cohorts to its ongoing Phase I study of CUDC-907 and increased target enrollment in the study from … Continue Reading
Read Now